TRVI

Trevi Therapeutics, Inc. (TRVI) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended September 30, 2024. Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), as well as prurigo nodularis. The company has no approved products and has not generated any product revenue.

Key Financial Metrics

Note: The company extinguished its Silicon Valley Bank term loan in May 2023. There is no outstanding debt as of September 30, 2024.

Material Changes vs. Prior Period

• Increased Burn Rate: Net loss for the nine months ended September 30, 2024, increased by approximately 72% compared to the same period in 2023, driven primarily by higher clinical development costs.
• R&D Spend: Research and development expenses rose significantly (from $17.2M to $30.0M YTD) due to the advancement of the Phase 2b CORAL trial (IPF), Phase 2a RIVER trial (RCC), and the Human Abuse Potential (HAP) study.
• Liquidity Position: Total cash, cash equivalents, and marketable securities decreased from $76.6 million at September 30, 2023, to $65.5 million at September 30, 2024, reflecting operating cash outflows of $28.7 million for the nine-month period.
• Financing Activity: The company raised approximately $9.7 million net of commissions through its At-The-Market (ATM) sales agreement during the first nine months of 2024.

Guidance, Outlook, and Risks

• Clinical Milestones:
  • CORAL Trial (IPF): Reached 50% enrollment in October 2024. A sample size re-estimation analysis is expected in December 2024, with topline results anticipated in the first half of 2025.
  • RIVER Trial (RCC): Enrollment completed in October 2024. Topline data expected in Q1 2025.
  • HAP Study: Dosing complete; topline data expected in December 2024.
  • TIDAL Study: Screening initiated to evaluate respiratory physiology in IPF patients.
• Liquidity Outlook: Management believes existing resources ($65.5 million) will fund operations into the second half of 2026. However, the company expects to incur substantial additional expenses and will require further funding to complete development and commercialization.
• Key Risks:
  • Capital Needs: Failure to raise additional capital could force delays or abandonment of clinical programs.
  • Regulatory Uncertainty: Haduvio is an opioid-based drug; the FDA may require a Risk Evaluation and Mitigation Strategy (REMS) or classify it as a controlled substance based on HAP study results.
  • Single Product Dependence: The company's entire business relies on the success of Haduvio.
  • Supply Chain: Reliance on a single supplier (Mallinckrodt) for the active pharmaceutical ingredient, which has faced bankruptcy proceedings.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "second half of 2026" funding estimate against current burn rates and potential clinical trial cost overruns.
• ATM Utilization: Monitor the remaining capacity under the $75 million ATM sales agreement and the frequency of share sales, which may impact stock price dilution.
• Warrant Overhang: Review the significant number of outstanding warrants (approx. 37.1 million shares) and their exercise prices, which could dilute existing shareholders upon exercise.
• Clinical Enrollment: Confirm the outcome of the CORAL trial sample size re-estimation in December 2024, as an upsizing could materially increase costs and delay timelines.
• HAP Study Results: Assess the December 2024 HAP study data for any signals of abuse potential that could trigger restrictive FDA labeling or controlled substance scheduling.